SPYRE THERAPEUTICS, INC. Stock Split Ratio
SPYRE THERAPEUTICS, INC. (SYRE) reported Stock Split Ratio of 9.50% for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-13.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2018-03-13
- SPYRE THERAPEUTICS, INC. stockholders' equity note, stock split, conversion ratio for the quarter ending 2016-03-31 was 9.50%.
- SPYRE THERAPEUTICS, INC. stockholders' equity note, stock split, conversion ratio for fiscal 2017 was 9.50%, a 0.00% change from fiscal 2016.
- SPYRE THERAPEUTICS, INC. stockholders' equity note, stock split, conversion ratio for fiscal 2016 was 9.50%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|
| 2017-12-31 | 9.50% 10-K · filed 2018-03-13 | |||
| 2016-12-31 | 9.50% 10-K · filed 2017-03-23 | |||
| 2016-09-30 | 9.50% 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | 9.50% 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | 9.50% 10-Q · filed 2016-05-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |